Senti Bio Announces Additional $11.5M Of Financing; ~$10M Additional Investment In Private Placement Equity Financing; $1.5M From CIRM Grant First Announced In June 2024; Cash Runway Guidance Extended Into 2026
Senti Bio Announces Additional $11.5M Of Financing; ~$10M Additional Investment In Private Placement Equity Financing; $1.5M From CIRM Grant First Announced In June 2024; Cash Runway Guidance Extended Into 2026
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has secured an additional investment of approximately $10.0 million in gross proceeds from Celadon Partners adding to the previously announced PIPE financing round.– Approximately $10 million additional investment in private placement equity financing –
— 对私募股权融资的额外投资约1000万美元 —
– $1.5 million from CIRM grant first announced in June 2024 –
— 来自 2024 年 6 月首次宣布的 CirM 拨款中的 150 万美元 —
– Cash runway guidance extended into 2026 –
— 现金跑道指导方针延长至2026年 —
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has secured an additional investment of approximately $10.0 million in gross proceeds from Celadon Partners adding to the previously announced PIPE financing round.
加利福尼亚州南旧金山，2025年1月6日（GLOBE NEWSWIRE）——Senti Biosciences, Inc.（纳斯达克股票代码：SNTI）（“Senti Bio” 或 “公司”）是一家使用其专有基因回路平台开发下一代细胞和基因疗法的临床阶段生物技术公司，今天宣布，已从Celadon Partners获得总收益约1,000万美元的额外投资宣布了PIPE轮融资。
This additional funding brings the total raised in the round to $47.6 million.
这笔额外资金使本轮筹集的资金总额达到4,760万美元。
